Clinical Trial Application approved for CryptiVax-1001 OVACT trial in Advanced High-Grade Serous Ovarian Cancer April 28, 2026
FDA Fast Track Designation for Lunresertib in Combination with Zedoresertib for Genomic-Defined Platinum-Resistant Ovarian Cancer April 21, 2026
Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer Presented April 21, 2026
Ph 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) Presented April 21, 2026
Results Announced from Ph 2 SKB264-II-06/MK-2870-002 Study of Sacituzumab Tirumotecan (Sac-TMT) in ovarian cancer cohort and the cervical cancer cohorts April 21, 2026
Mocertatug rezetecan achieved confirmed ORR of 62% in platinum-resistant ovarian cancer (PROC) and 67% in recurrent/advanced endometrial cancer in BEHOLD-1 study April 15, 2026
Gilead to Acquire Tubulis Adding ADC and Next Gen Platform to Further Strengthen Oncology Pipeline April 15, 2026
2-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy in Recurrent Low-Grade Serous Ovarian Cancer presented April 15, 2026
Results from Ph 2 IMGN853-0420 trial show ORR of 62.7% with ELAHERE + chemo followed by ELAHERE monotherapy in patients with ≥50% FRα-expressing PSOC April 15, 2026
CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer April 7, 2026
European Commission Approves KEYTRUDA + Paclitaxel ± Bevacizumab for the Treatment of Adults With PD-L1 (CPS ≥1) Platinum-Resistant Recurrent Ovarian Carcinoma Who Have Received One or Two Prior Systemic Treatment Regimens April 7, 2026
Japan’s MHLW approves risovalisib (Risovalisib Mesilate Hydrate or Heitzexin) after chemo for ovarian clear cell carcinoma with advanced PIK3CA gene mutations March 31, 2026
Updated Ph 2 Data Showing Continued Improvement in Median OS with IMNN-001 in Women with Newly Diagnosed Advanced Ovarian Cancer Reported March 31, 2026
FDA Fast Track designation granted to ZW191 for the treatment of patients with advanced or metastatic platinum-resistant ovarian cancer (PROC) March 31, 2026
FDA Approves Lifyorli™ (relacorilant) Plus Nab-Paclitaxel for Treatment of Patients with Platinum-Resistant Ovarian Cancer March 31, 2026
Persevere Therapeutics Launches as a Clinical-Stage Oncology Company with a Novel Ph 1b/2a Agent and Announces First Close of Seed Financing March 10, 2026
Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission March 10, 2026
OS Primary Endpoint Met in Ph 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer March 3, 2026
Randomized Ph 2a Study of Low Dose Alnodesertib Plus Gemcitabine Achieves Primary Endpoint in Platinum-Resistant Ovarian Cancer March 3, 2026
KEYTRUDA + Paclitaxel +/- Bevacizumab Significantly Improved OS vs Paclitaxel +/- Bevacizumab in Patients With Platinum-Resistant Recurrent Ovarian Cancer March 3, 2026
